Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
14.33
-0.01 (-0.07%)
Mar 4, 2026, 4:00 PM EST - Market closed
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Amicus Therapeutics stock have a consensus rating of "Buy" and an average price target of $27.25, which forecasts a 90.16% increase in the stock price over the next year. The lowest target is $11 and the highest is $108.
Price Target: $27.25 (+90.16%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 22, 2026.
Analyst Ratings
The average analyst rating for Amicus Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Hold | 1 | 1 | 1 | 5 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 9 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $16 → $15 | Strong Buy → Hold | Downgrades | $16 → $15 | +1.19% | Jan 22, 2026 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $17 → $15 | Buy → Hold | Downgrades | $17 → $15 | +1.19% | Dec 29, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $17 → $15 | Strong Buy → Hold | Downgrades | $17 → $15 | +1.19% | Dec 22, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 19, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades $21 → $15 | Buy → Hold | Downgrades | $21 → $15 | +1.19% | Dec 19, 2025 |
Financial Forecast
Revenue This Year
764.22M
from 634.21M
Increased by 20.50%
Revenue Next Year
906.32M
from 764.22M
Increased by 18.59%
EPS This Year
0.34
from -0.09
EPS Next Year
0.68
from 0.34
Increased by 97.79%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 822.2M | 989.2M | |||
| Avg | 764.2M | 906.3M | |||
| Low | 721.2M | 829.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 29.6% | 29.4% | |||
| Avg | 20.5% | 18.6% | |||
| Low | 13.7% | 8.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.58 | 0.92 | |||
| Avg | 0.34 | 0.68 | |||
| Low | 0.24 | 0.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 170.7% | |||
| Avg | - | 97.8% | |||
| Low | - | -11.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.